Dr. Tsai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1221 Madison St
Suite 500
Seattle, WA 98104Phone+1 206-386-2828Fax+1 206-386-3782
Summary
- Dr. Michaela Tsai is a medical oncologist and hematologist. She is the medical director of the breast oncology program at the Swedish Cancer Institute in Seattle, WA. She also directs the breast clinical research program, the survivorship program, and the cancer genetics program.
Education & Training
Harvard Medical SchoolClass of 1998
Duke UniversityBS, Chemistry and Religion, Summa Cum Laude, 1990 - 1994
Certifications & Licensure
WA State Medical License 2021 - 2025
AK State Medical License 2023 - 2024
MN State Medical License 2000 - 2021- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
- PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsSafety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.Jacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar
British Journal of Haematology. 2024-05-01 - 3 citationsIncidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020.Michael J Wagner, Vinod Ravi, Stephanie K Schaub, Ed Y Kim, Jeremy Sharib
JAMA Network Open. 2024-04-01 - 83 citationsBlood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.Edward S Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M Shagan
Nature Medicine. 2022-05-01
Press Mentions
70-Gene Signature Impacts Treatment Decisions in Breast CAOctober 29th, 2017
New Data Shows Agendia’s MammaPrint® Can Prevent Under and over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence ScoreJune 7th, 2016- Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to Their Medical Advisory BoardJune 1st, 2016
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
